Peter Palese

List of Publications by Year
in descending order

341 papers	46,654 citations	1094 112 h-index	2233 201 g-index
362 all docs	362 docs citations	362 times ranked	26765 citing authors

#	ARTICLE	IF	CITATIONS
1	Influenza Virus Transmission Is Dependent on Relative Humidity and Temperature. PLoS Pathogens, 2007, 3, e151.	2.1	1,259
2	Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus. Science, 2005, 310, 77-80.	6.0	1,158
3	Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems. Virology, 1998, 252, 324-330.	1.1	913
4	A novel influenza A virus mitochondrial protein that induces cell death. Nature Medicine, 2001, 7, 1306-1312.	15.2	901
5	Influenza. Nature Reviews Disease Primers, 2018, 4, 3.	18.1	880
6	The biology of influenza viruses. Vaccine, 2008, 26, D49-D53.	1.7	802
7	Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology, 1974, 61, 397-410.	1.1	779
8	Human host factors required for influenza virus replication. Nature, 2010, 463, 813-817.	13.7	755
9	Rescue of Influenza A Virus from Recombinant DNA. Journal of Virology, 1999, 73, 9679-9682.	1.5	741
10	Broadly neutralizing hemagglutinin stalkâ€"specific antibodies require FcÎ³R interactions for protection against influenza virus in vivo. Nature Medicine, 2014, 20, 143-151.	15.2	680
11	Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists. Journal of Virology, 2007, 81, 548-557.	1.5	601
12	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	5.8	590
13	Glycan Microarray Analysis of the Hemagglutinins from Modern and Pandemic Influenza Viruses Reveals Different Receptor Specificities. Journal of Molecular Biology, 2006, 355, 1143-1155.	2.0	570
14	Activation of Interferon Regulatory Factor 3 Is Inhibited by the Influenza A Virus NS1 Protein. Journal of Virology, 2000, 74, 7989-7996.	1.5	533
15	Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature, 2006, 443, 578-581.	13.7	515
16	A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission. Science, 2007, 315, 655-659.	6.0	508
17	Influenza A Virus NS1 Protein Prevents Activation of NF-Î°B and Induction of Alpha/Beta Interferon. Journal of Virology, 2000, 74, 11566-11573.	1.5	505
18	Influenza: old and new threats. Nature Medicine, 2004, 10, S82-S87.	15.2	502

#	Article	IF	Citations
19	Transmission of Influenza Virus in a Mammalian Host Is Increased by PB2 Amino Acids 627K or 627E/701N. PLoS Pathogens, 2009, 5, e1000252.	2.1	497
20	Advances in the development of influenza virus vaccines. Nature Reviews Drug Discovery, 2015, 14, 167-182.	21.5	496
21	Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane. Journal of Virology, 2007, 81, 9812-9824.	1.5	472
22	Amplification, expression, and packaging of a foreign gene by influenza virus. Cell, 1989, 59, 1107-1113.	13.5	469
23	Pathogenicity of Influenza Viruses with Genes from the 1918 Pandemic Virus: Functional Roles of Alveolar Macrophages and Neutrophils in Limiting Virus Replication and Mortality in Mice. Journal of Virology, 2005, 79, 14933-14944.	1.5	466
24	Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain. MBio, 2010, 1, .	1.8	460
25	The Ebola virus VP35 protein functions as a type I IFN antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 12289-12294.	3.3	442
26	Structure of the Uncleaved Human H1 Hemagglutinin from the Extinct 1918 Influenza Virus. Science, 2004, 303, 1866-1870.	6.0	440
27	Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature, 2012, 489, 526-532.	13.7	434
28	The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3. Journal of Virology, 2003, 77, 7945-7956.	1.5	432
29	A Single Mutation in the PB1-F2 of H5N1 (HK/97) and 1918 Influenza A Viruses Contributes to Increased Virulence. PLoS Pathogens, 2007, 3, e141.	2.1	427
30	Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1350-1355.	3.3	378
31	Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies. Journal of Virology, 2013, 87, 6542-6550.	1.5	360
32	Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature, 1978, 274, 334-339.	13.7	358
33	A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor Binding Specificity. Journal of Virology, 2005, 79, 11533-11536.	1.5	356
34	Immune history profoundly affects broadly protective B cell responses to influenza. Science Translational Medicine, 2015, 7, 316ra192.	5.8	353
35	Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. Journal of Clinical Investigation, 2016, 126, 605-610.	3.9	349
36	Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins. Journal of Virology, 2003, 77, 1501-1511.	1.5	348

#	Article	IF	Citations
37	Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10736-10741.	3.3	339
38	Influenza Virus NS1 Protein Counteracts PKR-Mediated Inhibition of Replication. Journal of Virology, 2000, 74, 6203-6206.	1.5	328
39	The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity. Gene, 1980, 8, 315-328.	1.0	323
40	The guinea pig as a transmission model for human influenza viruses. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9988-9992.	3.3	317
41	Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1. PLoS Pathogens, 2005, 1, e4.	2.1	306
42	High Temperature (30Â°C) Blocks Aerosol but Not Contact Transmission of Influenza Virus. Journal of Virology, 2008, 82, 5650-5652.	1.5	292
43	Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4309-4314.	3.3	288
44	Influenza virus hemagglutinin stalk-based antibodies and vaccines. Current Opinion in Virology, 2013, 3, 521-530.	2.6	286
45	The genes of influenza virus. Cell, 1977, 10, 1-10.	13.5	281
46	The Role of Interferon in Influenza Virus Tissue Tropism. Journal of Virology, 1998, 72, 8550-8558.	1.5	276
47	Influenza A Virus PB1-F2 Protein Contributes to Viral Pathogenesis in Mice. Journal of Virology, 2006, 80, 7976-7983.	1.5	276
48	Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18979-18984.	3.3	273
49	Toward a Universal Influenza Virus Vaccine: Prospects and Challenges. Annual Review of Medicine, 2013, 64, 189-202.	5.0	270
50	Cellular Proteins in Influenza Virus Particles. PLoS Pathogens, 2008, 4, e1000085.	2.1	268
51	Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2746-2751.	3.3	266
52	Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins. PLoS Pathogens, 2010, 6, e1000796.	2.1	251
53	A Proline-Rich Motif within the Matrix Protein of Vesicular Stomatitis Virus and Rabies Virus Interacts with WW Domains of Cellular Proteins: Implications for Viral Budding. Journal of Virology, 1999, 73, 2921-2929.	1.5	249
54	Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5986-5991.	3.3	248

#	Article	IF	Citations
55	Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2573-2578.	3.3	244
56	Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes. Journal of Virology, 2012, 86, 5774-5781.	1.5	241
57	Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host and Microbe, 2016, 19, 800-813.	5.1	238
58	Influenza B virus evolution: Co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. Virology, 1988, 163, 112-122.	1.1	227
59	Recombinant Newcastle Disease Virus as a Vaccine Vector. Journal of Virology, 2001, 75, 11868-11873.	1.5	220
60	Attenuation of Equine Influenza Viruses through Truncations of the NS1 Protein. Journal of Virology, 2005, 79, 8431-8439.	1.5	220
61	Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza. Journal of Virology, 2009, 83, 1742-1753.	1.5	217
62	Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5777-5782.	3.3	213
63	Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction. Journal of Virology, 2003, 77, 9522-9532.	1.5	208
64	Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8203-8208.	3.3	207
65	Nipah Virus V and W Proteins Have a Common STAT1-Binding Domain yet Inhibit STAT1 Activation from the Cytoplasmic and Nuclear Compartments, Respectively. Journal of Virology, 2004, 78, 5633-5641.	1.5	206
66	The Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon at the Level of the MAVS Adaptor Protein. PLoS Pathogens, 2011, 7, e1002067.	2.1	206
67	Nuclear Import of Influenza Virus RNA Can Be Mediated by Viral Nucleoprotein and Transport Factors Required for Protein Import. Journal of Biological Chemistry, 1995, 270, 22701-22704.	1.6	205
68	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	15.2	204
69	Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13133-13138.	3.3	197
70	Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology, 1987, 160, 336-345.	1.1	193
71	Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nature Immunology, 2007, 8, 1188-1193.	7.0	189
72	Specific Residues of the Influenza A Virus Hemagglutinin Viral RNA Are Important for Efficient Packaging into Budding Virions. Journal of Virology, 2007, 81, 9727-9736.	1.5	188

#	Article	IF	Citations
73	A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Molecular Therapy, 2020, 28, 1569-1584.	3.7	188
74	Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology, 2012, 7, 347-367.	1.0	185
75	Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet, The, 2020, 395, e42-e43.	6.3	182
76	Transmission of Influenza Virus via Aerosols and Fomites in the Guinea Pig Model. Journal of Infectious Diseases, 2009, 199, 858-865.	1.9	179
77	Nuclear Localization of the Nipah Virus W Protein Allows for Inhibition of both Virus- and Toll-Like Receptor 3-Triggered Signaling Pathways. Journal of Virology, 2005, 79, 6078-6088.	1.5	174
78	Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice. MBio, 2015, 6, e02556.	1.8	173
79	Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3166-3171.	3.3	171
80	Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell, 2015, 162, 160-169.	13.5	171
81	Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines. PLoS Pathogens, 2010, 6, e1000745.	2.1	166
82	Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon by Binding to MAVS and Decreasing Mitochondrial Membrane Potential. Journal of Virology, 2012, 86, 8359-8366.	1.5	162
83	Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20248-20253.	3.3	159
84	NPI-1, the human homolog of SRP-1, Interacts with influenza virus nucleoprotein. Virology, 1995, 206, 116-125.	1.1	158
85	Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis. Science Translational Medicine, 2013, 5, 198ra107.	5.8	157
86	Cellular Splicing Factor RAF-2p48/NPI-5/BAT1/UAP56 Interacts with the Influenza Virus Nucleoprotein and Enhances Viral RNA Synthesis. Journal of Virology, 2001, 75, 1899-1908.	1.5	154
87	Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11931-11936.	3.3	153
88	One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9101-9106.	3.3	150
89	A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy<i>In Vivo</i>. Journal of Virology, 2012, 86, 6179-6188.	1.5	150
90	Guiding the Immune Response against Influenza Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the Globular Head Domain. Journal of Virology, 2014, 88, 699-704.	1.5	148

#	Article	IF	Citations
91	A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates. PLoS ONE, 2012, 7, e43603.	1.1	146
92	Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nature Communications, 2013, 4, 2854.	5.8	146
93	An influenza virus containing nine different RNA segments. Virology, 1991, 185, 291-298.	1.1	144
94	Highly Conserved Regions of Influenza A Virus Polymerase Gene Segments Are Critical for Efficient Viral RNA Packaging. Journal of Virology, 2008, 82, 2295-2304.	1.5	144
95	7a Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates p38 Mitogen-Activated Protein Kinase. Journal of Virology, 2006, 80, 785-793.	1.5	142
96	Colocalization of Different Influenza Viral RNA Segments in the Cytoplasm before Viral Budding as Shown by Single-molecule Sensitivity FISH Analysis. PLoS Pathogens, 2013, 9, e1003358.	2.1	142
97	Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3064-3069.	3.3	140
98	H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice. Journal of Virology, 2013, 87, 4728-4737.	1.5	138
99	The influenza c virus glycoprotein (HE) exhibits receptor-binding (hemagglutinin) and receptor-destroying (esterase) activities. Virology, 1987, 160, 419-425.	1.1	137
100	Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans. Journal of Virology, 2014, 88, 13260-13268.	1.5	136
101	Making Better Influenza Virus Vaccines?. Emerging Infectious Diseases, 2006, 12, 61-65.	2.0	135
102	A Single N66S Mutation in the PB1-F2 Protein of Influenza A Virus Increases Virulence by Inhibiting the Early Interferon Response <i>In Vivo</i>. Journal of Virology, 2011, 85, 652-662.	1.5	135
103	PB1-F2 Expression by the 2009 Pandemic H1N1 Influenza Virus Has Minimal Impact on Virulence in Animal Models. Journal of Virology, 2010, 84, 4442-4450.	1.5	134
104	Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nature Communications, 2017, 8, 846.	5.8	134
105	<i>In Vivo</i> Bioluminescent Imaging of Influenza A Virus Infection and Characterization of Novel Cross-Protective Monoclonal Antibodies. Journal of Virology, 2013, 87, 8272-8281.	1.5	133
106	Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System. Journal of Visualized Experiments, 2013, , e51112.	0.2	132
107	Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nature Immunology, 2017, 18, 464-473.	7.0	131
108	Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets. Journal of Virology, 2014, 88, 3432-3442.	1.5	128

#	Article	IF	Citations
109	Negative-strand RNA viruses: genetic engineering and applications.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11354-11358.	3.3	127
110	Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13849-13854.	3.3	127
111	An Unconventional NLS is Critical for the Nuclear Import of the Influenza A Virus Nucleoprotein and Ribonucleoprotein. Traffic, 2005, 6, 205-213.	1.3	127
112	The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model. Journal of Virology, 2011, 85, 11235-11241.	1.5	127
113	Transmission of a 2009 Pandemic Influenza Virus Shows a Sensitivity to Temperature and Humidity Similar to That of an H3N2 Seasonal Strain. Journal of Virology, 2011, 85, 1400-1402.	1.5	123
114	Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells. Journal of Virology, 2011, 85, 6015-6023.	1.5	119
115	Transmission of Pandemic H1N1 Influenza Virus and Impact of Prior Exposure to Seasonal Strains or Interferon Treatment. Journal of Virology, 2010, 84, 21-26.	1.5	118
116	Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio, 2016, 7, e01996-15.	1.8	116
117	Advances in Universal Influenza Virus Vaccine Design and Antibody Mediated Therapies Based on Conserved Regions of the Hemagglutinin. Current Topics in Microbiology and Immunology, 2014, 386, 301-321.	0.7	115
118	Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. Journal of Clinical Investigation, 2015, 125, 1255-1268.	3.9	115
119	Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Research, 2003, 95, 3-12.	1.1	114
120	NS1-Binding Protein (NS1-BP): a Novel Human Protein That Interacts with the Influenza A Virus Nonstructural NS1 Protein Is Relocalized in the Nuclei of Infected Cells. Journal of Virology, 1998, 72, 7170-7180.	1.5	114
121	Noncumulative sequence changes in the hemagglutinin genes of influenza C virus isolates. Virology, 1985, 146, 221-232.	1.1	113
122	A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. Npj Vaccines, 2017, 2, 26.	2.9	113
123	Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin. MBio, 2017, 8, .	1.8	112
124	Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin. Journal of Virology, 2014, 88, 13580-13592.	1.5	110
125	Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity, 2016, 44, 46-58.	6.6	110
126	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	5.8	110

#	Article	IF	Citations
127	Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis. Science, 2012, 335, 1463-1463.	6.0	108
128	Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5944-E5951.	3.3	108
129	A Sendai Virus-Derived RNA Agonist of RIG-I as a Virus Vaccine Adjuvant. Journal of Virology, 2013, 87, 1290-1300.	1.5	107
130	Effects of Influenza A Virus NS1 Protein on Protein Expression: the NS1 Protein Enhances Translation and Is Not Required for Shutoff of Host Protein Synthesis. Journal of Virology, 2002, 76, 1206-1212.	1.5	105
131	Evolution of human influenza a viruses in nature: Sequential mutations in the genomes of new H1N1 isolates. Cell, 1979, 18, 73-83.	13.5	104
132	Why Do Influenza Virus Subtypes Die Out? A Hypothesis. MBio, 2011, 2, .	1.8	103
133	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases, The, 2020, 20, 80-91.	4.6	103
134	Influenza B Virus NS1-Truncated Mutants: Live-Attenuated Vaccine Approach. Journal of Virology, 2008, 82, 10580-10590.	1.5	102
135	H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge. Journal of Virology, 2014, 88, 2340-2343.	1.5	102
136	Epidemiology of influenza C virus in man: Multiple evolutionary lineages and low rate of change. Virology, 1986, 153, 12-21.	1.1	100
137	Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. MBio, 2016, 7, .	1.8	100
138	Nonranom association of parental genes in influenza A virus recombinants. Virology, 1979, 95, 269-274.	1.1	99
139	Unraveling the Mystery of Swine Influenza Virus. Cell, 2009, 137, 983-985.	13.5	97
140	Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses. Cellular Immunology, 1996, 173, 96-107.	1.4	96
141	Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nature Microbiology, 2017, 2, 1415-1424.	5.9	96
142	Functional Replacement of the Carboxy-Terminal Two-Thirds of the Influenza A Virus NS1 Protein with Short Heterologous Dimerization Domains. Journal of Virology, 2002, 76, 12951-12962.	1.5	94
143	Hemagglutinin-Pseudotyped Green Fluorescent Protein-Expressing Influenza Viruses for the Detection of Influenza Virus Neutralizing Antibodies. Journal of Virology, 2010, 84, 2157-2163.	1.5	94
144	Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models. Journal of Virology, 2010, 84, 11219-11226.	1.5	94

#	Article	IF	Citations
145	Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. Journal of Virology, 2012, 86, 10302-10307.	1.5	93
146	Nonconserved Nucleotides at the 3â€² and 5â€² Ends of an Influenza A Virus RNA Play an Important Role in Viral RNA Replication. Virology, 1996, 217, 242-251.	1.1	92
147	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. Journal of Virology, 2015, 89, 3221-3235.	1.5	92
148	Oseltamivir-Resistant Influenza A Viruses Are Transmitted Efficiently among Guinea Pigs by Direct Contact but Not by Aerosol. Journal of Virology, 2008, 82, 10052-10058.	1.5	90
149	Influenza vaccines: present and future. Journal of Clinical Investigation, 2002, 110, 9-13.	3.9	90
150	Oligonucleotide mapping: evaluation of its sensitivity by computer-simulation. Nucleic Acids Research, 1982, 10, 237-246.	6.5	88
151	Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nature Communications, 2018, 9, 4560.	5.8	88
152	Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Research, 1993, 29, 141-153.	1.1	85
153	Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses. Molecular Therapy, 2009, 17, 697-706.	3.7	84
154	Is a Universal Influenza Virus Vaccine Possible?. Annual Review of Medicine, 2020, 71, 315-327.	5.0	84
155	Budding Capability of the Influenza Virus Neuraminidase Can Be Modulated by Tetherin. Journal of Virology, 2011, 85, 2480-2491.	1.5	83
156	Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form. Molecular and Biochemical Parasitology, 1992, 51, 49-54.	0.5	82
157	The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses. Journal of Virology, 2011, 85, 12825-12829.	1.5	82
158	Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3954-3959.	3.3	81
159	Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Research, 2008, 80, 124-134.	1.9	81
160	Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones. Journal of Virology, 2015, 89, 3610-3618.	1.5	80
161	Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model. Journal of Virology, 2009, 83, 2803-2818.	1.5	79
162	Mutational analysis of the influenza virus vRNA promoter. Virus Research, 1993, 28, 99-112.	1.1	78

#	Article	IF	Citations
163	Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature, 2022, 602, 314-320.	13.7	78
164	1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans. Journal of Infectious Diseases, 2013, 207, 98-105.	1.9	77
165	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62, 103132.	2.7	77
166	Transmission of influenza virus in temperate zones is predominantly by aerosol, in the tropics by contactA hypothesis. PLOS Currents, 2009, 1, RRN1002.	1.4	77
167	Is It Possible to Develop a â€œUniversalâ€• Influenza Virus Vaccine?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028845.	2.3	75
168	Long-term survival of influenza virus infected club cells drives immunopathology. Journal of Experimental Medicine, 2014, 211, 1707-1714.	4.2	74
169	Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine, 2009, 27, 3766-3774.	1.7	73
170	Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs. Journal of Virology, 2013, 87, 7793-7804.	1.5	73
171	Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. Cell Host and Microbe, 2018, 24, 18-24.	5.1	73
172	Mapping of the influenza virus genome II. Identification of the P1, P2, and P3 genes. Virology, 1977, 76, 114-121.	1.1	72
173	Influenza A Virus PB1-F2: A Small Protein with a Big Punch. Cell Host and Microbe, 2007, 2, 207-209.	5.1	72
174	Rewiring the RNAs of influenza virus to prevent reassortment. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15891-15896.	3.3	72
175	Nipah Virus Edits Its P Gene at High Frequency To Express the V and W Proteins. Journal of Virology, 2009, 83, 3982-3987.	1.5	72
176	Transmission of Influenza B Viruses in the Guinea Pig. Journal of Virology, 2012, 86, 4279-4287.	1.5	72
177	The Influenza A Virus PB2, PA, NP, and M Segments Play a Pivotal Role during Genome Packaging. Journal of Virology, 2012, 86, 7043-7051.	1.5	72
178	Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain. Journal of Infectious Diseases, 2019, 219, S62-S67.	1.9	72
179	Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. Journal of Virology, 2017, 91, .	1.5	70
180	Comparison of the three large polymerase proteins of influenza A, B, and C viruses. Virology, 1989, 171, 458-466.	1.1	69

#	Article	IF	Citations
181	Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets. Journal of Virology, 2016, 90, 3268-3273.	1.5	69
182	Molecular weights of RNA segments of influenza A and B viruses. Virology, 1978, 88, 394-399.	1.1	68
183	Influenza vaccines: present and future. Journal of Clinical Investigation, 2002, 110, 9-13.	3.9	68
184	Universal influenza virus vaccines: need for clinical trials. Nature Immunology, 2014, 15, 3-5.	7.0	66
185	Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for <i>In Vivo</i> Protection in a Serum Transfer Mouse Challenge Model. MBio, 2017, 8, .	1.8	66
186	A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. Npj Vaccines, 2016, 1, .	2.9	65
187	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 2022, 28, 383-391.	15.2	65
188	Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins. Cell Reports, 2015, 11, 1331-1338.	2.9	64
189	Protection from the 2009 H1N1 Pandemic Influenza by an Antibody from Combinatorial Survivor-Based Libraries. PLoS Pathogens, 2010, 6, e1000990.	2.1	63
190	Influenza B and C Virus NEP (NS2) Proteins Possess Nuclear Export Activities. Journal of Virology, 2001, 75, 7375-7383.	1.5	61
191	H5N1 influenza viruses: Facts, not fear. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2211-2213.	3.3	61
192	Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Immunity, 2020, 53, 1230-1244.e5.	6.6	61
193	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	2.1	61
194	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 2021, 12, 6197.	5.8	61
195	Nucleotide sequence of the influenza A/duck/Alberta/60/76 virus NS RNA: Conservation of the NS1/NS2 overlapping gene structure in a divergent influenza virus RNA segment. Virology, 1981, 113, 397-402.	1.1	59
196	Effective replication of human influenza viruses in mice lacking a major Î±2,6 sialyltransferase. Virus Research, 2007, 126, 9-18.	1.1	59
197	Pause on Avian Flu Transmission Research. Science, 2012, 335, 400-401.	6.0	58
198	Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies. Antimicrobial Agents and Chemotherapy, 2015, 59, 4162-4172.	1.4	58

#	Article	IF	Citations
199	Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk Antibodies. PLoS ONE, 2013, 8, e79194.	1.1	58
200	Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus. MBio, 2019, 10, .	1.8	57
201	The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes. Virus Research, 1995, 37, 37-47.	1.1	56
202	The Nucleoprotein of Newly Emerged H7N9 Influenza A Virus Harbors a Unique Motif Conferring Resistance to Antiviral Human MxA. Journal of Virology, 2015, 89, 2241-2252.	1.5	56
203	Sequential passage of influenza virus in embryonated eggs or tissue culture: Emergence of mutants. Virology, 1980, 107, 424-433.	1.1	55
204	Attenuation of Influenza A Virus mRNA Levels by Promoter Mutations. Journal of Virology, 1998, 72, 6283-6290.	1.5	55
205	Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology, 2007, 122, 28-37.	2.0	54
206	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Journal of Virology, 2020, 94, .	1.5	54
207	NS1-Truncated Live Attenuated Virus Vaccine Provides Robust Protection to Aged Mice from Viral Challenge. Journal of Virology, 2012, 86, 10293-10301.	1.5	53
208	Development of Influenza B Universal Vaccine Candidates Using the â€œMosaicâ€•Hemagglutinin Approach. Journal of Virology, 2019, 93, .	1.5	53
209	Differences in protein patterns of influenza A viruses. Virology, 1977, 76, 122-128.	1.1	52
210	Influenza Virus Transmission: Basic Science and Implications for the Use of Antiviral Drugs During a Pandemic. Infectious Disorders - Drug Targets, 2007, 7, 318-328.	0.4	52
211	Influenza A viruses with truncated NS1 as modified live virus vaccines: Pilot studies of safety and efficacy in horses. Equine Veterinary Journal, 2009, 41, 87-92.	0.9	52
212	Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nature Communications, 2010, 1, 28.	5.8	52
213	Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge. Journal of Virology, 2014, 88, 3976-3985.	1.5	52
214	Antigenic variants of influenza viruses: Marked differences in the frequencies of variants selected with different monoclonal antibodies. Virology, 1980, 102, 458-462.	1.1	51
215	A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine, 2008, 26, 522-531.	1.7	51
216	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. Journal of Clinical Investigation, 2018, 128, 4992-4996.	3.9	51

#	Article	IF	Citations
217	Apical Budding of a Recombinant Influenza A Virus Expressing a Hemagglutinin Protein with a Basolateral Localization Signal. Journal of Virology, 2002, 76, 3544-3553.	1.5	49
218	Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin. Journal of Virology, 2013, 87, 8235-8240.	1.5	48
219	Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Frontiers in Immunology, 2019, 10, 756.	2.2	48
220	Universal epitopes of influenza virus hemagglutinins?. Nature Structural and Molecular Biology, 2009, 16, 233-234.	3.6	47
221	Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine, 2019, 49, 96-105.	2.7	47
222	Current Challenges in Vaccinology. Frontiers in Immunology, 2020, 11, 1181.	2.2	47
223	What Can We Learn from Reconstructing the Extinct 1918 Pandemic Influenza Virus?. Immunity, 2006, 24, 121-124.	6.6	46
224	Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine, 1999, 17, 887-892.	1.7	45
225	Influenza A Virus RNA Polymerase Has the Ability To Stutter at the Polyadenylation Site of a Viral RNA Template during RNA Replication. Journal of Virology, 1999, 73, 5240-5243.	1.5	45
226	Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3861-3866.	3.3	44
227	A Reassortment-Incompetent Live Attenuated Influenza Virus Vaccine for Protection against Pandemic Virus Strains. Journal of Virology, 2011, 85, 6832-6843.	1.5	43
228	Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice. Journal of Virology, 2011, 85, 2235-2246.	1.5	42
229	A Novel Small Molecule Inhibitor of Influenza A Viruses that Targets Polymerase Function and Indirectly Induces Interferon. PLoS Pathogens, 2012, 8, e1002668.	2.1	42
230	Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins. Journal of Virology, 2016, 90, 3789-3793.	1.5	42
231	Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10172-10177.	3.3	42
232	A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model. Cell Reports, 2018, 22, 1-7.	2.9	42
233	Complementation and analysis of an NP mutant of influenza virus. Virus Research, 1989, 12, 97-111.	1.1	41
234	RNA pattern of â€˜Swineâ€™ influenza virus isolated from man is similar to those of other swine influenza viruses. Nature, 1976, 263, 528-530.	13.7	40

#	Article	IF	Citations
235	A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. Npj Vaccines, 2019, 4, 31.	2.9	40
236	Development of Novel Influenza Virus Vaccines and Vectors. Journal of Infectious Diseases, 1997, 176, S45-S49.	1.9	38
237	Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8 + -T-Cell Epitope Derived from the Circumsporozoite Protein of Plasmodium yoelii. Journal of Virology, 2003, 77, 11859-11866.	1.5	38
238	First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Science Translational Medicine, 2021, 13, .	5.8	38
239	Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors. Journal of Virology, 2004, 78, 9366-9375.	1.5	37
240	Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. Journal of Virology, 2016, 90, 2544-2550.	1.5	36
241	High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS ONE, 2015, 10, e0125618.	1.1	35
242	Evolutionary relatedness of the predicted gene product of RNA segment 2 of the Tick-Borne Dhori virus and the PB1 polymerase gene of influenza viruses. Virology, 1991, 182, 1-7.	1.1	34
243	A Seven-Segmented Influenza A Virus Expressing the Influenza C Virus Glycoprotein HEF. Journal of Virology, 2008, 82, 6419-6426.	1.5	34
244	Transmission Studies Resume for Avian Flu. Science, 2013, 339, 520-521.	6.0	34
245	Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head and Neck, 2011, 33, 1394-1399.	0.9	33
246	Efficient Transmission of Pandemic H1N1 Influenza Viruses with High-Level Oseltamivir Resistance. Journal of Virology, 2012, 86, 5386-5389.	1.5	33
247	Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice. ImmunoHorizons, 2019, 3, 133-148.	0.8	33
248	Chimeric Influenza A Viruses with a Functional Influenza B Virus Neuraminidase or Hemagglutinin. Journal of Virology, 2003, 77, 9116-9123.	1.5	32
249	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Journal of Virology, 2017, 91, .	1.5	32
250	Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. Current Opinion in Immunology, 2018, 53, 51-57.	2.4	32
251	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. MBio, 2021, 12, e0190821.	1.8	32
252	An avian tumor virus promoter directs expression of plasmid genes in Escherichia coli. Gene, 1981, 16, 217-225.	1.0	31

#	Article	IF	Citations
253	Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion. Journal of Virology, 2017, 91, .	1.5	30
254	Expression of Transgenes from Newcastle Disease Virus with a Segmented Genome. Journal of Virology, 2008, 82, 2692-2698.	1.5	29
255	A Nine-Segment Influenza A Virus Carrying Subtype H1 and H3 Hemagglutinins. Journal of Virology, 2010, 84, 8062-8071.	1.5	29
256	The influenza A virus protein PB1-F2. Virulence, 2011, 2, 542-546.	1.8	29
257	Don't censor life-saving science. Nature, 2012, 481, 115-115.	13.7	29
258	Transfectant Influenza A Viruses Are Effective Recombinant Immunogens in the Treatment of Experimental Cancer. Virology, 1998, 249, 89-97.	1.1	28
259	Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene. Journal of Virology, 2003, 77, 7411-7424.	1.5	28
260	Identification of Small Molecules with Type I Interferon Inducing Properties by High-Throughput Screening. PLoS ONE, 2012, 7, e49049.	1.1	27
261	An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. PLoS ONE, 2018, 13, e0194830.	1.1	27
262	Human Genes and Influenza. Journal of Infectious Diseases, 2008, 197, 1-3.	1.9	26
263	Peering into the Crystal Ball: Influenza Pandemics and Vaccine Efficacy. Cell, 2014, 157, 294-299.	13.5	26
264	Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. MBio, 2016, 7, e00257.	1.8	26
265	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine, 2022, 45, 101323.	3.2	26
266	Catching a Moving Target. Science, 2011, 333, 834-835.	6.0	24
267	Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Journal of Virology, 2018, 92, .	1.5	24
268	Variation in Influenza Virus Genes. , 1989, , 319-359.		24
269	Detection of single base substitutions in influenza virus RNA molecules by denaturing gradient gel electrophoresis of RNA-RNA or DNA-RNA heteroduplexes. Virology, 1986, 150, 55-64.	1.1	22
270	The influenza C virus NS gene: evidence for a spliced mRNA and a second NS gene product (NS2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	1.1	22

#	Article	IF	Citations
271	A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein. ACS Infectious Diseases, 2015, 1, 98-109.	1.8	22
272	Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. Journal of Virology, 2019, 93, .	1.5	21
273	Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice. Journal of General Virology, 2000, 81, 737-742.	1.3	21
274	A Majority of Infectious Newcastle Disease Virus Particles Contain a Single Genome, while a Minority Contain Multiple Genomes. Journal of Virology, 2012, 86, 10852-10856.	1.5	20
275	Serum- and Glucocorticoid-Regulated Kinase 1 Is Required for Nuclear Export of the Ribonucleoprotein of Influenza A Virus. Journal of Virology, 2013, 87, 6020-6026.	1.5	20
276	Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Molecular Therapy - Methods and Clinical Development, 2021, 22, 84-95.	1.8	20
277	Neuraminidase aus Schweinenieren. Reinigung und Eigenschaften. Hoppe-Seyler's Zeitschrift FÃ¼r Physiologische Chemie, 1968, 349, 1169-1178.	1.7	19
278	Sequence analysis and receptor specificity of the hemagglutinin of a recent influenza H2N2 virus isolated from chicken in North America. Glycoconjugate Journal, 2006, 23, 93-99.	1.4	19
279	Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. Journal of Virology, 2020, 94, .	1.5	19
280	Common Sequence at the 5â€² Ends of the Segmented RNA Genomes of Influenza A and B Viruses. Journal of Virology, 1978, 25, 312-318.	1.5	19
281	Genetic analysis of influenza virus. Current Opinion in Genetics and Development, 1992, 2, 77-81.	1.5	18
282	The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. Journal of Virology, 2018, 92, .	1.5	18
283	Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase. Journal of Virology, 2019, 93, .	1.5	18
284	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. Npj Vaccines, 2019, 4, 51.	2.9	18
285	Expression of antisense RNA fails to inhibit influenza virus replication. Virus Research, 1989, 14, 141-159.	1.1	17
286	Recombinant Vectors as Influenza Vaccines. Current Topics in Microbiology and Immunology, 2009, 333, 243-267.	0.7	17
287	Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies. Journal of Virology, 2015, 89, 12226-12231.	1.5	17
288	Mutation of Neuraminidase Cysteine Residues Yields Temperature-Sensitive Influenza Viruses. Journal of Virology, 1999, 73, 8095-8103.	1.5	17

#	Article	IF	Citations
289	Attenuated Influenza Virus Construct with Enhanced Hemagglutinin Protein Expression. Journal of Virology, 2012, 86, 5782-5790.	1.5	16
290	Influenza Virus Infection in Guinea Pigs Raised as Livestock, Ecuador. Emerging Infectious Diseases, 2012, 18, 1135-1138.	2.0	15
291	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine, 2022, 40, 3621-3632.	1.7	15
292	Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines, 2021, 9, 40.	2.1	14
293	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Frontiers in Immunology, 2021, 12, 791764.	2.2	14
294	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Molecular Therapy, 2022, 30, 2024-2047.	3.7	14
295	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiology Spectrum, 2022, 10, .	1.2	14
296	Assembly of lipid-containing viruses. Journal of Supramolecular Structure, 1974, 2, 496-511.	2.3	12
297	A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. Antiviral Research, 2013, 100, 29-37.	1.9	12
298	An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines, 2019, 7, 117.	2.1	12
299	Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein. Journal of Virology, 2019, 93, .	1.5	12
300	Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Cancer-Specific Newcastle Disease Virus. Journal of Gastrointestinal Surgery, 2010, 14, 7-14.	0.9	11
301	H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model. MBio, 2020, 11, .	1.8	11
302	Reassortment Continuum. , 1984, , 144-151.		10
303	Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1â€"2 randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 1062-1075.	4.6	10
304	Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
305	Novel method of detecting single base substitutions in RNA molecules by differential melting behavior in solution. Genomics, 1988, 3, 217-223.	1.3	9
306	Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells. Influenza and Other Respiratory Viruses, 2007, 1, 95-104.	1.5	9

#	Article	IF	Citations
307	Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Frontiers in Immunology, 2021, 12, 746447.	2.2	9
308	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
309	An Egg-Derived Sulfated<i>N</i>-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. MBio, 2021, 12, e0083821.	1.8	8
310	The makings of a killer. Nature Medicine, 2002, 8, 927-928.	15.2	7
311	Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. Scientific Reports, 2021, 11, 22164.	1.6	7
312	Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses. Antiviral Research, 2017, 142, 12-15.	1.9	6
313	The 1918 Influenza Pandemic: Lessons from the Past Raise Questions for the Future. Monographs in Virology, 2008, , 272-286.	0.6	5
314	Influenza Virus. , 2016, , 1009-1058.		5
315	Response to Comment on â€œSeroevidence for H5N1 Influenza Infections in Humans: Meta-Analysisâ€• Science, 2012, 336, 1506-1506.	6.0	4
316	A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. Scientific Reports, 2020, 10, 9750.	1.6	4
317	In memoriam â€“ Richard M. Elliott (1954â€“2015). Journal of General Virology, 2015, 96, 1975-1978.	1.3	4
318	RAPID EVOLUTION OF HUMAN INFLUENZA VIRUSES. , 1986, , 53-68.		4
319	Profile of Charles M. Rice, Ralf F. W. Bartenschlager, and Michael J. Sofia, 2016 Laskerâ€“DeBakey Clinical Medical Research Awardees. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13934-13937.	3.3	3
320	The Hemagglutinin Gene of Influenza Viruses. Topics in Infectious Diseases, 1978, , 49-57.	0.6	3
321	Influenza Viruses: High Rate of Mutation and Evolution. , 2018, , 123-135.		3
322	Genetic variation of human influenza viruses. Trends in Biochemical Sciences, 1980, 5, III-V.	3.7	2
323	Germ of an idea. Nature, 1987, 329, 480-480.	13.7	2
324	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2

#	Article	IF	Citations
325	High-complexity extracellular barcoding using a viral hemagglutinin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2767-2769.	3.3	2
326	Interaction between NS1 and Cellular MAVS Contributes to NS1 Mitochondria Targeting. Viruses, 2021, 13, 1909.	1.5	2
327	Influenza Virus: The Biology of a Changing Virus. , 2011, , 3-26.		2
328	Infectious Influenza Viruses from cDNA-Derived RNA: Reverse Genetics. , 1993, , 107-114.		2
329	Series Introduction: New directions in vaccine research. Journal of Clinical Investigation, 2002, 109, 1517-1518.	3.9	2
330	A broadly protective antibody. Nature, 2017, 551, 310-311.	13.7	1
331	Genome Plasticity of Influenza Viruses. , 0, , 162-177.		1
332	Influenza virus: The biology of a changing virus. , 2008, , 9-30.		1
333	Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.. Journal of Clinical Oncology, 2014, 32, 3051-3051.	0.8	1
334	Influenza Viruses: Genome Structure, Transcription and Replication of Viral RNA. , 1987, , 299-316.		0
335	Viruses and the Innate Immune System. , 2005, , 1-18.		0
336	Influenza pandemics: past and future. Retrovirology, 2006, 3, 1.	0.9	0
337	Live Attenuated Influenza Virus Vaccines: NS1 Truncation as an Approach to Virus Attenuation. , 2011, , 195-221.		0
338	The Long Road to a Universal Influenza Virus Vaccine. Proceedings (mdpi), 2020, 50, .	0.2	0
339	A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro. Proceedings (mdpi), 2020, 50, .	0.2	0
340	Correlation of High Evolutionary Rate of Influenza A Viruses in Man with High Mutation Rate Measured in Tissue Culture: A Hypothesis. , 1988, , 23-27.		0
341	Evolutionary Lineages and Molecular Epidemiology of Influenza A, B, and C Viruses. , 1990, , 119-129.		0